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Alzheimer’s disease (AD) is the most common cause of dementia worldwide. As
advancing age is the greatest risk factor for developing AD, the number of those afflicted
is expected to increase markedly with the aging of the world’s population. The inability to
definitively diagnose AD until autopsy remains an impediment to establishing effective
targeted treatments. Neuroimaging has enabled in vivo visualization of pathological
changes in the brain associated with the disease, providing a greater understanding of
its pathophysiological development and progression. However, neuroimaging biomarkers
do not yet offer clear advantages over current clinical diagnostic criteria for them to
be accepted into routine clinical use. Nonetheless, current insights from neuroimaging
combined with the elucidation of biochemical and molecular processes in AD are informing
the ongoing development of new imaging techniques and their application. Much of this
research has been greatly assisted by the availability of transgenic mouse models of AD. In
this review we summarize the main efforts of neuroimaging in AD in humans and in mouse
models, with a specific focus on β-amyloid, and discuss the potential of new applications
and novel approaches.
Keywords: neuroimaging, Alzheimer’s disease, MRI, PET, mouse models, CT, biomarkers
INTRODUCTION
Alzheimer’s disease (AD) is the most common cause of demen-
tia worldwide, accounting for 65–75% of all cases of dementia
(Bianchetti and Trabucch, 2001; Brookmeyer et al., 2011). It is
characterized by neurodegenerative changes that are associated
with early deficits in memory, but inexorably progresses to affect
other cognitive domains. With progression of the disease, the
affected individual’s ability to function is eroded until all inde-
pendence is lost. The annual incidence of AD rises markedly with
age, from 53 new cases per 1000 people aged 65 to 74, to 170 new
cases per 1000 people aged 75–84, and 230 new cases per 1000
people aged over 85 (Alzheimers, 2011). Similarly its prevalence
increases exponentially with age, in the United States rising from
2.32% in those aged 71–79 years to 29.60% in those aged over 90
(Brookmeyer et al., 2011). Approximately 5% of cases occur as an
inheritable trait passed on in a Mendelian manner, wherein the
onset of symptoms develop relatively early in life, leading these to
be termed early onset AD (EOAD) (van Gool and Eikelenboom,
2000; Rocchi et al., 2003; Minati et al., 2009). In contrast, the vast
majority of cases occur sporadically as late onset AD (LOAD) and
are multi-factorial in etiology. However, the single greatest risk
factor for LOAD is age. Consequently, with increasing longevity
and the overall aging of the world’s growing population, the num-
ber of people with dementia is projected to increase by 234%,
from a currently estimated 24.3 million people to 81.1 million
people by 2040 (Ferri et al., 2005). This presents immense health
and economic challenges for both the present and the future.
A major impediment to the management of AD is the inability
to definitively diagnose the disease until post-mortem examina-
tion. The initial diagnosis is presumptive, based upon clinical
evaluation and neuropsychological testing and the fulfillment of
certain criteria as laid out in the International Classification of
Disease (10th Revision; ICD-10), the Diagnostic and Statistical
Manual of Mental Disorders (Fourth Edition, Text Revision;
DSM-IV-TR) and the National Institute of Neurological and
Communicative Disorders and Stroke-Alzheimer’s Disease and
Related Disorders Association (NINCDS-ADRDA) (Honig and
Mayeux, 2001; Morris, 2003; Minati et al., 2009). Application
of these criteria yields a diagnostic accuracy of 80–90% when
compared to the histopathological gold standard (Morris, 2003;
Masters et al., 2006; Minati et al., 2009). However, a variety of
disorders can lead to or mimic dementia or can co-exist with
AD, thereby worsening its progression. While conditions such as
stroke, brain tumors, normal pressure hydrocephalus, infections
and vitamin deficiency can be readily excluded, other causes of
dementia that must be differentiated from AD, including vascu-
lar dementia, frontotemporal dementia and dementia with Lewy
bodies may present greater diagnostic challenges. Furthermore, it
is now evident that patients who will develop AD may present
as a subset of people with mild cognitive impairment (MCI).
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These patients have subjective or objective impairment in a single
cognitive domain that does not impair their functional capacity.
The recognition of MCI as a prodrome to AD and that neu-
ropathology develops well in advance of any clinical symptoms
gives greater impetus to developing diagnostic and prognostic
biomarkers for AD.
Neuroimaging presents immense potential for developing reli-
able biomarkers that can be viewed in the living brain. Key
neuropathological features on which the definitive diagnosis of
AD relies, seen at post-mortem in the brains of AD patients,
are general atrophy of the cortex, neuron and synapse loss,
extracellular plaques composed of insoluble β-amyloid (Aβ) and
intraneuronal neurofibrillary tangles (NFTs) consisting of hyper-
phosphorylated tau (Perl, 2010). Developments in imaging enable
these features to be visualized, either directly or indirectly, pro-
viding important information on the disease processes in vivo.
Early and subtle structural changes, evident as atrophy in vul-
nerable brain regions such as the hippocampus and entorhinal
cortex, can be detected with high-resolution magnetic resonance
imaging (MRI). These changes are reflected at the cellular level by
alterations in metabolites detected by magnetic resonance spec-
troscopy (MRS). Further changes are evident with functional
imaging using functional MRI (fMRI), single positron emission
computed tomography (SPECT) and positron emission tomog-
raphy (PET). Functional abnormalities are surrogates of synaptic
dysfunction/ loss in early AD and of neuronal loss with disease
progression.
However, the most significant development is the ability to
image the amyloid plaques, whose deposition and accumula-
tion are widely viewed as fundamental to the pathological cas-
cade leading to AD. Neuroimaging of plaques in humans using
amyloid-labeling PET tracers and in transgenic (Tg) animal mod-
els, particularly mouse models of AD, has greatly expanded the
understanding of amyloid in the context of AD pathogenesis. Yet,
the picture that is emerging is that significant plaque accumula-
tion occurs prior to the earliest clinical symptoms and amyloid
burden has reached a steady state by the time of clinically diag-
nosed AD. It may also be less important in terms of neurotoxicity
than other soluble oligomeric species of Aβ. Understanding the
true role of amyloid pathology in the pathogenesis of AD will
provide meaningful insight into the search for effective targeted
therapeutics for this disease, but it will rely as much on devel-
oping neuroimaging in animal AD models as the validation of
techniques in humans.
In this review we will focus on Aβ, as it is currently the most
widely studied neuroimaging biomarker for the diagnosis and
monitoring of disease. Furthermore, whilst opinions are divided,
a large proportion of the scientific community believe that amy-
loid is a primary mediator of disease pathogenesis in AD. We
will briefly discuss the current understanding of the pathological
mechanisms that provide the theoretical underpinnings for amy-
loid imaging, therein exploring the appropriateness of its use as a
biomarker of AD. Finally we will examine the development amy-
loid imaging in Tg mouse models for application in pre-clinical
and clinical research. In particular, we will attempt to highlight
the technical challenges faced in validating amyloid imaging for
these applications.
PATHOPHYSIOLOGY OF ALZHEIMER’S DISEASE
CENTRAL ROLE OF β-AMYLOID IN ALZHEIMER’S DISEASE
Central to the pathogenesis of AD is the Aβ protein, pro-
duced from the cleavage of the amyloid precursor protein (APP).
Over 80% of cases of EOAD are accounted for by muta-
tions in either the gene for APP or one of two other pro-
teins presenilin-1 (PS1) and presenilin-2 (PS2), which form
part of the γ-secretase complex (Rocchi et al., 2003). These
mutations lead to an accelerated production of Aβ that exceeds
its clearance mechanisms and subsequently results in its accu-
mulation in the brain. In contrast, LOAD develops from
impaired clearance of Aβ due to various factors (Zetzsche et al.,
2010).
Cleavage of APP occurs sequentially by the action of either α-
secretase or β-secretase (BACE-1) and γ-secretase (Masters et al.,
2006; Murphy and LeVine, 2010). Whilst the majority of APP is
processed by α-secretase to result in non-amyloidogenic cleav-
age products (Masters et al., 2006; Murphy and LeVine, 2010),
a proportion is cleaved by β-secretase and γ-secretase to result
in the formation of Aβ peptides (Murphy and LeVine, 2010).
The predominant forms of Aβ produced are Aβ40 and Aβ42, of
which the former is more common. However, the latter has a
greater propensity for aggregating into oligomers and fibrils and
is believed to be the more toxic product (Ballard et al., 2011).
Degradation of Aβ has been attributed to a number of mecha-
nisms. Extracellular enzymatic degradation may be carried out
by neprilysin and insulin degrading enzyme, while intracellu-
lar lysosomal degradation may also play a role (Murphy and
LeVine, 2010). In addition, the activity of microglia may also
play an important role in clearance of both soluble Aβ and its
fibrillar aggregates (Agostinho et al., 2010; Lee and Landreth,
2010).
The mechanisms leading to Aβ aggregation are not fully
understood but a number of factors may be involved. It is likely
that protein folding plays a crucial role in amyloidogenesis, as
proteins seek to attain a quaternary structure that has a min-
imum energy and hence most stable conformation (Bharadwaj
et al., 2009). An alternative but stable “misfolded” state may make
Aβ prone to aggregation and mutations associated with FADmay
predispose tomisfolding (Bharadwaj et al., 2009). Similar to prion
diseases, this abnormal aggregation and precipitation could be
the cause of amyloidosis in AD. Aβ aggregation may be a conse-
quence of interactions with other factors such as the metals zinc
and copper, which are dysregulated in the AD brain (Bush, 2008;
Kawahara, 2010).
HowAβ aggregates exert their neurotoxic effects is still unclear.
Amyloid has been shown to be directly toxic to neuronal cell
cultures (Golde et al., 2006). Evidence suggests a number of path-
ways by which Aβ acts. Chief among these is oxidative stress
and inflammation, which have an established role in the biology
of aging, and calcium dyshomeostasis (Reddy, 2009; Kawahara,
2010). In AD, these pathological processes have the early conse-
quences of synaptic dysfunction and culminate later in neuronal
loss. Amyloid burden, however, correlates poorly with disease
severity, suggesting a lesser role for insoluble Aβ fibrils, while sol-
uble Aβ oligomers appear to play the major part in neurotoxicity
(Minati et al., 2009).
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MECHANISMS OF AMYLOID-β PATHOGENESIS
Evidence strongly suggests oxidative stress has an early and
important role in the pathogenesis of AD (Maynard et al., 2005;
Agostinho et al., 2010; Muller et al., 2010; Santos et al., 2010).
Redox reactions occurring during normal cellular respiration
produce reactive oxygen species (ROS) such as superoxide anion,
hydroxyl radical and hydrogen peroxide. ROS interact with and
alter cellular components, including nucleic acids, lipids and
proteins, causing damage to important cellular structures and
impairing their functions. Molecular mechanisms have evolved
to minimize and repair oxidative damage but they may be over-
whelmed, tipping the balance toward oxidative stress. The conse-
quence of accumulated oxidative damage is a molecular cascade
resulting in cellular dysfunction and ultimately, the triggering of
pathways leading to cell death (Sultana et al., 2009).
In AD, accelerated oxidative stress is likely driven by Aβ
pathology in a number of ways. One mechanism is by interac-
tions with and the dysregulation of important biological metals.
Another is by impairment of mitochondria, the organelles in
which cellular respiration resides and the main source of endoge-
nous ROS in cells (Casadesus et al., 2004; Agostinho et al.,
2010). Increased APP in mitochondrial membranes may be one
cause of mitochondrial dysfunction in neurons (Kawahara, 2010).
Furthermore, Aβ may also disrupt mitochondrial membrane
function by inserting into it as oligomers, creating calcium-
permeable channels (Reddy, 2009; Kawahara, 2010). This affects
the flux of calcium across the membrane with resultant mito-
chondrial structural and functional damage (Reddy, 2009). Aβ
oligomers are also incorporated into neuronal membranes, lead-
ing to a wider dysregulation of calcium homeostasis in the neuron
(Kawahara, 2010). Disruption of calcium homeostasis affects cel-
lular function and can trigger apoptotic pathways of cellular
death. Therefore, Aβ-induced calcium dyshomeostasis may act
synergistically with oxidative stress to cause neuronal dysfunction
and death.
Both the increasing presence of Aβ aggregates and the release
of substances by dying neurons incite neuroinflammation, which
is an early event in AD (Agostinho et al., 2010; Glass et al.,
2010; Lee and Landreth, 2010). Inflammatory mediators such
as cytokines and activated complement components are elevated
in vulnerable brain regions in AD (Agostinho et al., 2010; Lee
and Landreth, 2010). Furthermore, the presence of activated
microglia and astrogliosis around senile plaques support the role
of inflammation (Agostinho et al., 2010; Glass et al., 2010; Lee
and Landreth, 2010). Microglia and astrocytes may have neu-
roprotective functions by their scavenging and clearance of Aβ
aggregates (Agostinho et al., 2010; Lee and Landreth, 2010).
However, they may also mediate neurotoxic effects by release of
pro-inflammatory cytokines, chemokines, ROS and complement
proteins (Lee and Landreth, 2010). Furthermore, APP mRNA is
upregulated by IL-1, an inflammation cytokine, further promot-
ing amyloidosis and reinforcing a self-perpetuating cycle (Rogers
and Lahiri, 2004).
How Aβ pathology is related to tau pathology remains unclear.
However, there is growing evidence to support the direct or indi-
rect interaction of Aβ with tau to accelerate NFT formation. It
is likely that Aβ pathology lies upstream of tau pathology, as
genetic mutations leading to elevated Aβ levels or aggregation also
leads to NFT formation while no reciprocal relationship with tau
accumulation has been found (Blurton-Jones and Laferla, 2006).
Phosphorylation of tau at various sites promotes their aggrega-
tion and NFT formation while Aβ is shown to activate several
tau kinases, providing a straight forward mechanism for induc-
tion of NFT formation by Aβ (Blurton-Jones and Laferla, 2006;
Mi and Johnson, 2006). Other suggested links are: Aβ-induced
inflammation with resulting induction and enhancement of tau
phosphorylation by inflammatory cytokines; Aβ-induced pro-
teasomal impairment of tau degradation; and dysregulation of
axonal transport with possible bidirectional effects, leading to
increases in Aβ as well as tau (Blurton-Jones and Laferla, 2006).
Accumulation of Aβ and abnormal tau pathology exerts an
effect on synapses, affecting their density and function and conse-
quently the function of neuronal circuits within the brain (Selkoe,
2008; Arendt, 2009; Palop and Mucke, 2010). Histopathological
examination of AD brain tissue from patients within 2–4 years
after clinical onset of AD reveals significant reductions in post-
synaptic dendritic spine density. These changes are most marked
in the hippocampus and least prominent in the occipital cor-
tex, exhibiting differences in the regional distribution of synaptic
alterations that matches the pattern outlined in the Braak and
Braak staging system (Arendt, 2009). Furthermore, this reduc-
tion in synaptic density is already evident in patients with
MCI (Arendt, 2009). Aβ oligomers, both synthetic and naturally
occurring, have been shown to mediate synaptic dysfunction,
impairing long-term potentiation as well as enhancing long-
term depression (Selkoe, 2008; Shankar et al., 2008; Sultana
et al., 2009; Palop and Mucke, 2010). Studies have shown ele-
vated Aβ decreases excitatory glutamatergic synaptic transmission
by reductions in post-synaptic α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid receptor (AMPA) receptors and N-
methyl-D-aspartate (NMDA) receptors (Palop andMucke, 2010).
Furthermore, accumulation of abnormally phosphorylated tau
species within synaptic terminals in AD brains and APP trans-
genic mice has been reported, suggesting a link between tau and
synaptic pathology (Arendt, 2009). Synaptic dysfunction conse-
quently leads to alterations in brain activity and connectivity,
evident as regional alterations in activity on functional studies
(Bokde et al., 2009).
In summary, these data support a primary role for Aβ in the
pathogenesis of AD (although clearly there are other aspects that
are also very important). As such, the ability to detect Aβ in the
brain of living individuals has long been heralded as a key to
allow the earliest detection of AD, with the subsequent benefit
of expedited treatment and the hope of extending the number
of disease free years. There are several important caveats to this
however. Firstly, Aβ accumulates in the brains of normal individ-
uals. In the earliest stages this appears to correlate with subjective
cognitive complaints, although not with objective measurements
of memory and executive function (Amariglio et al., 2012). This
may, however, represent an early indicator for the subsequent
development of AD. The time frame between the first detec-
tion of Aβ by neuroimaging and the clinical manifestation of
AD may also be quite long, as Aβ accumulates at quite a slow
rate (Villemagne et al., 2013). Furthermore, whilst Aβ generally
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increases continuously from the levels found in younger healthy
controls to those found in AD, it does not do so in a linear fash-
ion, with rates of deposition slowing in more advanced stages of
disease (Villemagne et al., 2013). That being said, understanding
the natural history of Aβ formation and deposition will provide
a greater understanding of the overall dynamics of the potential
progression from healthy control, through MCI (individuals in
this group have a transition rate to AD of approximately 30.5%
Ellis et al., 2014) and into AD. This will ultimately provide a better
prognostic indication for the individual with a given Aβ burden.
In addition, such data will facilitate better controlled clinical stud-
ies by allowing Aß burden to be used as an intake/cutoff criteria
for inclusion in drug studies.
Another important caveat is in regards to whether the level
of Aβ accumulation, as observed through neuroimaging method-
ologies, is a good correlate of cognitive function—this remains a
contentious issue, with the majority of studies suggesting that it is
a poormarker of disease severity. However, a recent study demon-
strated, for the first time, that there was an association between
the rate of Aβ deposition and memory decline in a cohort of AD
patients (Villemagne et al., 2013). These findings arose out of the
Australian Imaging, Biomarkers and Lifestyle study, which is a
multi-year prospective study of 1112 individuals with either AD,
MCI or no pathology (age-matched healthy controls), and per-
haps demonstrates the need for such large, well-controlled studies
in order to discern correlations between Aβ burden and cognitive
function. Thus, there are several important outcomes, both for
the individual and for the community, that serve as important
rationales for continuing neuroimaging initiatives in AD.
NEUROIMAGING IN ALZHEIMER’S DISEASE
The current clinical role of neuroimaging in AD is the exclusion
of any other disease pathology that may be causative of cognitive
decline (Ferreira and Busatto, 2011; McKhann et al., 2011). These
include cerebrovascular diseases, tumor, subdural haematoma or
other causes of dementia, including dementia with Lewy bod-
ies and frontotemporal dementia (Lee et al., 2003; Small et al.,
2008; Mistur et al., 2009). Additionally, imaging may reveal cere-
bral atrophy evidenced by ventricular and sulcal enlargement,
non-specific signs which can only support the diagnosis of AD
as they are also observed in normal aging and other dementias.
The two imaging modalities in routine use are computed tomog-
raphy (CT) and MRI. Of the two, MRI is preferred due to its
far superior soft tissue resolution and hence its ability to pro-
vide detailed structural information (Ferreira and Busatto, 2011).
Nonetheless, CT has limited utility in the diagnostic work up,
particularly where MRI is contraindicated (Ferreira and Busatto,
2011).
Recently, with advances in imaging technology, studies using
MRI and PET neuroimaging of AD have identified a number of
potential biomarkers (Ferreira and Busatto, 2011). However, these
biomarkers have yet to gain acceptance as a diagnostic criteria
(McKhann et al., 2011). Consequently their main application is
in the area of research, with the aim of furthering understanding
into the pathological processes of AD and also of improving their
reliability for routine clinical use. With continuing advances, the
potential of imaging biomarkers draws closer to realization.
MAGNETIC RESONANCE IMAGING
The high resolution provided by MRI has made it especially use-
ful in studying the morphological details of the AD brain in situ.
Analyses in quantitative structural studies of brain atrophy are
commonly applied to gray matter changes in T1-weighted images
and have been either cross-sectional or longitudinal (Vemuri and
Jack, 2010). Cross-sectional volumetric analysis of medial tem-
poral lobe (MTL) structures can be done qualitatively by visual
assessment or quantitatively by analysis of regions of interest
either usingmanual tracing andmeasurement or automated tech-
niques (Vemuri and Jack, 2010). Voxel-based analysis has also
been applied for comparisons between an AD group and a control
group to detect subtle differences (Glodzik-Sobanska et al., 2005;
Vemuri and Jack, 2010). Longitudinal methods of analysis include
global atrophy quantification by analysis of brain boundary shifts,
and tensor-based morphometry, a 3-dimensional voxel-based
method (Glodzik-Sobanska et al., 2005; Coimbra et al., 2006;
Vemuri and Jack, 2010).While brain atrophy is not specific to AD,
studies have revealed atrophy of the MTL is well correlated with
changes in cognition and disease progression (Coimbra et al.,
2006; Frisoni et al., 2010; Vemuri and Jack, 2010). In particular,
atrophy of the hippocampus and entorhinal cortex is of particular
value as a biomarker due to their involvement in the earliest stage
of disease and strong correlation with NFT pathology (Glodzik-
Sobanska et al., 2005; Ramani et al., 2006; Vemuri and Jack, 2010).
Hippocampal volume is reduced in MCI patients by 10–15%
while in mild and moderate AD it is reduced by 15–30% and
30–40% respectively (Lehericy et al., 2007; Frisoni et al., 2010).
The rate of atrophy is also predictive of progression, being 4–6%
per year in MCI/AD patients compared to 1–2% in age-matched
controls (Coimbra et al., 2006). As will be discussed later, MR
imaging has been successfully applied to animal models of AD,
and in some cases has provided unique observations of potential
relevance to the human condition. Volumetric losses present out-
side of forebrain structures, for example, have been reported to
predict sites of future amyloid formation (Badea et al., 2010).
Structural studies have also utilized other MR imaging tech-
niques to image pathological alterations in both gray and white
matter. Diffusion weighted imaging (DWI) with apparent diffu-
sion coefficient (ADC) mapping and diffusion tensor imaging
(DTI) has been used to investigate the white matter changes in
areas such as the temporal lobe, hippocampus and corpus callo-
sum (Ramani et al., 2006; Small et al., 2008; Stebbins andMurphy,
2009). In particular, DTI is capable of assessing microstruc-
tural and connective changes in the hippocampus and its related
structures, arising from neuronal loss and axonal degeneration
(Yakushev et al., 2011a,b; Hattori et al., 2012). Alternatively, mag-
netization transfer imaging (MTI) is able to detect structural
damage as a reduction in the magnetization transfer rate (MTR)
reflects decreased tissue homogeneity from pathological changes
such as neuronal loss and gliosis in gray matter, and demyelina-
tion and axonal loss in white matter (Glodzik-Sobanska et al.,
2005; Ramani et al., 2006). DecreasedMTR is found in both white
and gray matter in AD patients and has been reported in the
hippocampus in very mild AD (Ramani et al., 2006).
At a molecular level, cellular changes associated with neu-
ronal pathology can be studied using MRS. The most commonly
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studied metabolites in MRS experiments of the brains of AD
patients are N-acetyl-aspartate (NAA), choline and creatinine,
which are associated with neuronal function, membrane turnover
and energy consumption respectively (Lee et al., 2003; Coimbra
et al., 2006; Scott et al., 2011). NAA has been found to be
decreased in AD, consistent with neuronal damage (Coimbra
et al., 2006). As the levels of choline or creatinine are relatively
unchanged, the ratio of NAA to these metabolites may be a useful
biomarker for AD (Lee et al., 2003; Coimbra et al., 2006). Other
metabolites are also being currently investigated for their value
in early diagnosis. Examples include myo-inositol (mIns), which
may be a marker of glial activation and hence neuroinflamma-
tion, lactate for monitoring anaerobic metabolism indicative of
hypoxia and ischaemia, and glutamine/glutamate for evaluating
regulation of neurotransmission (Ashford et al., 2011).
While neuronal loss is an obvious endpoint resulting from the
progression of AD pathology, it is now evident that this is pre-
ceded by neuronal dysfunction. This can be measured by changes
in cellular metabolic rate, which on a regional level can be visu-
alized in vivo as changes in the metabolic demand reflected by
decreased vascular perfusion and oxygen consumption (Wu and
Small, 2006). Consequently there are a number of functional
MRI (fMRI) studies that have assessed the consequence of neu-
ropathology in terms of neuronal activity and connectivity. These
studies are based either on changes in cerebral blood flow and
cerebral blood volume or changes revealed by the blood oxygen
level dependent (BOLD) effect (Wu and Small, 2006; Brickman
et al., 2009; Beckmann, 2011). Estimation of changes in cerebral
blood flow and cerebral blood volume involves either the injec-
tion of intravenous paramagnetic contrast, such as gadolinium or
superparamagnetic iron oxide nanoparticles or the technique of
arterial spin labeling (ASL) (Wu and Small, 2006; Brickman et al.,
2009; Beckmann, 2011). In contrast, the BOLD effect utilizes
the paramagnetic properties of deoxyhaemoglobin. Activation
therefore increases CBF out of keeping to metabolic needs. This
leads to an increase in oxyhaemoglobin and a relative decrease
in deoxyhaemoglobin which leads to a relative increase in signal
on T2∗ weighted imaging (Wu and Small, 2006; Brickman et al.,
2009; Beckmann, 2011). FMRI studies have identified abnormal-
ities in activity associated with a variety of cognitive tasks in
a number of regions (Dickerson and Sperling, 2009; Sperling
et al., 2010). Compared to healthy older controls, AD patients
are reported to exhibit decreased hippocampal and parahip-
pocampus activity, as well as decreased activity in the frontal and
prefrontal regions (Sperling et al., 2010). Also, AD patients show
less coordinated activity in the default mode network (DMN),
a functional network consisting of the posterior cingulate, hip-
pocampus, lateral inferior parietal and medial frontal lobes, that
is most active at rest and reduces in activity during the perfor-
mance of cognitive tasks (Small et al., 2008; Bokde et al., 2009;
Dickerson and Sperling, 2009; Sperling et al., 2010).
Though imaging functional and structural consequences has
provided many insights into AD, it is the potential to visual-
ize molecular pathology that has stirred the imagination in MRI
research. Since the first observations by Benveniste et al. (1999)
that hypointensities on T∗2-weighted MRI of ex vivo AD brains
corresponded to neuritic plaques there has been great interest
in the use of MRI in AD. Despite contrary findings by Dhenain
et al. (2002), research into the development of MRI techniques
to improve visualization and quantification of Aβ deposits in vivo
has been ongoing. However, much of the imaging of human AD
brains has been done ex vivo (Benveniste et al., 1999; Dhenain
et al., 2002; House et al., 2007, 2008; Schrag et al., 2010; Nabuurs
et al., 2011). Analyses of amyloid plaques suggest their inher-
ent contrast on T∗2-weighted imaging is attributable to increased
iron content relative to surrounding tissues (Benveniste et al.,
1999; Nakada et al., 2008; Nabuurs et al., 2011). Similar to
other neurodegenerative diseases such as Parkinson’s disease, iron
dyshomeostasis has an important and early role in the disease
process (Bartzokis et al., 2004). Abnormal Fe accumulation in the
AD brain is evident from MR measurements of transverse rela-
tion rates (R2) in post-mortem studies (House et al., 2007, 2008).
However, while these studies found a correlation between iron
and R2, amyloid plaque density was not correlated with iron con-
centrations. Nonetheless, plaque-associated iron can potentially
be harnessed to enhance their contrast by susceptibility-weighted
imaging (SWI) in living patients (Nakada et al., 2008).
Further work is still needed to validate the clinical use of in vivo
functional and plaque MRI in living patients with AD. For plaque
imaging, one need is for improvement in the time efficiency of
the scanning while achieving the required contrast and resolu-
tion. Another problem lies in the difficulty in correlating this
imaging with histology. This is partly due to artifacts arising from
other sources of iron (blood vessels, micro-hemorrhages) or as
a result of head motion during long scanning times (Versluis
et al., 2010). Because of this, there have been very few in vivo
studies in living subjects (Nakada et al., 2008; Versluis et al.,
2010). There are also limitations related to functional imaging
with ASL and BOLD. Firstly, there is potential bias from the use
of external stimuli and differences in cognitive task performance,
which requires carefully constructed experimental paradigms for
study validity. Secondly, high temporal resolution in the order of
seconds is needed to capture transient evoked changes, making
this technique very sensitive to head motion and compromis-
ing spatial resolution. Thirdly, disease related changes to brain
structure make changes in responses difficult to interpret. Finally,
fMRI produces relative rather than quantitative measures of brain
activity, which can be problematic when applied to diagnos-
tic or longitudinal monitoring purposes (Brickman et al., 2009;
Dickerson and Sperling, 2009).
RADIONUCLIDE IMAGING
Early radionuclide imaging in ADmade use of PET and SPECT to
evaluate functional alterations in the brain (Mosconi et al., 2010).
SPECT analysis using Tc-99-labeled hexamethylpropyleneamine
oxime (Tc-99-HMPAO) is able to show a global reduction in
cerebral blood flow along with focal changes in terms of tem-
poroparietal hypoperfusion (Lee et al., 2003; Coimbra et al.,
2006). However, the predictive accuracy of SPECT for diagnosing
AD is variable but generally found to be less than PET, making
it of limited clinical use (Lee et al., 2003; Coimbra et al., 2006).
The most common PET tracer used in functional studies is 2-
[18Flfluoro-2-Deoxy-D-glucose (FDG). FGD PET studies show a
specific regional pattern of cerebral glucose metabolism in AD
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compared to controls. Deficits are consistently observed in the
temporoparietal, MTL and posterior cingulate cortices, and later
in the frontal cortex as the disease progresses (Lee et al., 2003;
Coimbra et al., 2006; Mosconi et al., 2010). Notably the primary
sensory, motor and visual cortices, cerebellum, striatum and basal
ganglia are preserved (Lee et al., 2003; Mosconi et al., 2010).
This pattern can be used to distinguish AD from other forms
of dementia such as FTD and DWLB, and from cerebrovascular
disease (Mosconi et al., 2010). Evidence also suggests that these
metabolic reductions precede clinical symptoms as well as struc-
tural brain changes in predisposed people (Mistur et al., 2009;
Mosconi et al., 2010). Thus, it is suggested that FDG PET may be
useful in AD prognostication and as an adjunct to clinical assess-
ment for diagnosis (Lee et al., 2003; Mistur et al., 2009; Mosconi
et al., 2010).
More recently the development of peptide and antibody
probes has extended the use of PET beyond functional anal-
ysis to allow direct imaging of amyloid in vivo. Many of
the molecular probes are derivatives of histological dyes such
as Congo Red, thioflavin S and T, Acridine Orange and
Chrysamine-G (Coimbra et al., 2006; Fodero-Tavoletti et al.,
2009) or other molecules such as styrylbenzene. Two of the most
extensively used ligands are [11C]2-(4′-methylaminophenyl)-
6-hydroxybenzothiazole (Pittsburgh Compound B or PIB)
(Small et al., 2008; Fodero-Tavoletti et al., 2009; Mosconi
et al., 2010) and 2-(1-{6-[2-[18F]-fluoroethyl)(methyl)amino]-2-
naphthyl}ethylidene)malononitrile ( [18F]-FDDNP) (Small et al.,
2008; Fodero-Tavoletti et al., 2009; Mosconi et al., 2010). [18F]-
FDDNP was the first ligand successfully employed in humans
(Rabinovici and Jagust, 2009). However, it binds both diffuse and
dense-core amyloid along with tau (Coimbra et al., 2006; Mistur
et al., 2009; Rabinovici and Jagust, 2009), complicating its inter-
pretation and limiting its ability to differentiate AD from FTD
and other tauopathies.
PIB on the other hand binds with high affinity and specificity
to fibrillar Aβ (Coimbra et al., 2006; Fodero-Tavoletti et al., 2009;
Mosconi et al., 2010) and its in vivo PET signal correlates strongly
with in vitro measures of Aβ burden in post-mortem AD brains
(Rabinovici and Jagust, 2009). Studies have demonstrated ele-
vated retention of PIB in the brains of AD patients compared to
healthy controls (Coimbra et al., 2006; Small et al., 2008; Mosconi
et al., 2010). Significant PIB retention is found in 90% of clinically
diagnosed AD patients and approximately 60% of individuals
with MCI and 25–30% of normal elderly (Fodero-Tavoletti et al.,
2009; Mosconi et al., 2010). The regional distribution of high
retention in AD brains is in areas known to have high amyloid
deposition, most prominently the frontal cortex, parietal cortex,
lateral temporal cortex, posterior cingulated cortex/precuneus,
thalamus and striatum (Coimbra et al., 2006; Rabinovici and
Jagust, 2009; Mosconi et al., 2010). This pattern of distribution
allows differentiation of AD from FTD and Parkinson’s disease
(Mosconi et al., 2010), though significant retention and a simi-
lar pattern can also seen in DWLB (Fodero-Tavoletti et al., 2009;
Mosconi et al., 2010; Villemagne and Rowe, 2011). Imaging with
PIB has also provided important insights into the relationship
between amyloid burden and various markers of AD, such as cog-
nitive decline (Rowe et al., 2010), functional alterations (Hedden
et al., 2009; Rabinovici and Jagust, 2009; Shin et al., 2010, 2011;
Mormino et al., 2012) and regional brain atrophy (Jack et al.,
2008; Chetelat et al., 2010; Rowe et al., 2010).
A distinct disadvantage of PIB imaging is the short half-life of
11C, which is around 20min. This necessitates the existence of a
cyclotron in close proximity for production of the radioisotope
label. Labeling of PET imaging probes with 18F, a radioisotope
with a half-life of 110min removes this limitation (Mistur et al.,
2009). This approach has yielded a number of potential radio-
tracers, such as the 3’-fluoro-derivative of PIB, [18F]-3′-FPIB
(flutemetamol), and the strylpyridine and stilbene derivatives
[18F]-AV-45 (florbetapir) and [18F]-AV-1 (florbetaben) (Herholz
and Ebmeier, 2011; Vallabhajosula, 2011). Not surprisingly, [18F]-
3′-FPIB has near identical binding properties to PIB and per-
forms similarly in clinical studies (Vallabhajosula, 2011). [18F]-
AV-45 and [18F]-AV-1 also exhibit high affinity binding to
fibrillar amyloid similar to PIB (Herholz and Ebmeier, 2011;
Vallabhajosula, 2011). Ongoing development in amyloid-specific
PET ligands will improve their utility and widen their accessi-
bility for both research purposes and potentially routine clinical
applications.
ADVANCES FROM PRE-CLINICAL NEUROIMAGING IN
MOUSE MODELS
MODELS OF ALZHEIMER’S DISEASE
Animal models of AD have been extensively utilized in the inves-
tigation of the disease. The best model is the agedmonkey, such as
the Caribbean vervet monkey, lemur, cotton-top tamarin, rhesus
monkey and squirrel monkey (Philipson et al., 2010). However,
the time and cost involved makes primate models prohibitive for
routine use in research (Crews et al., 2010). There have been a
variety of other models including: rats, rabbits, dogs, the fruit
fly Drosophila melanogaster, the nematode Caenorhabditis elegans
and two types of fish, the sea lamprey, Petromyzon marinus and
the zebrafish (Götz et al., 2004; Götz and Götz, 2009; Crews
et al., 2010; Murphy and LeVine, 2010; Philipson et al., 2010).
However, the overwhelming majority of research has been car-
ried out in transgenic mouse models, which confer advantages in
terms of time and cost-effectiveness. At the same time they allow
the detailed analysis of pathological mechanisms at molecular,
anatomical and cognitive/behavioral levels.
Early models expressing human Aβ fragments, wild type
human APP, or fusion proteins containing the C-terminal frag-
ment of wild type APP or Aβ42 showed little or sparse AD-like
neuropathology or atypical Aβ deposition (Philipson et al., 2010).
However, with identification of EOAD-associated APPmutations,
transgenic mouse models were developed expressing high lev-
els of human APP incorporating these mutations. The first APP
transgenic mouse was the PDAPP mouse, which incorporated
one of the earliest APP mutations identified, the Indiana muta-
tion (V717F) (Philipson et al., 2010; Wisniewski and Sigurdsson,
2010). PDAPP mice develop both senile and diffuse plaques from
9 months of age and showed deficits in learning and memory
(Elder et al., 2010; Philipson et al., 2010). This was followed by
what is the most commonly used APP transgenic model, the
Tg2576 mouse harboring human APP with the Swedish muta-
tion (KM670/671NL) under the control of the prion promoter.
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These mice have five-fold overexpression of human APP, develop
Aβ deposits from 9 to 12 months of age and exhibit substantial
cerebral amyloid angiopathy (CAA) (Crews et al., 2010; Philipson
et al., 2010; Wisniewski and Sigurdsson, 2010). Other engineered
models have incorporated other mutations such as the London
(V717I), Arctic (E693G), Iowa (D694N), Flemish (A692G), or
Dutch (E693Q) mutation, resulting in various patterns of Aβ
deposition and pathology. For example, mice expressing the
Dutch and Iowa mutations have a propensity for CAA and dif-
fuse Aβ deposits. However, in most of these transgenic mice there
is a lack of neuronal loss. This lead to the development of mod-
els expressing combinations of different APP mutations in an
attempt to enhance neuronal toxicity, such as the APP23 mouse
which harbors both the Swedish and London mutations (Crews
et al., 2010; Elder et al., 2010; Philipson et al., 2010; Wisniewski
and Sigurdsson, 2010).
Following the identification of presenilin mutations, these
were similarly incorporated into mouse models. However, singly
transgenic mice with either PS1 or PS2 did not develop plaques
despite consistently showing elevated levels of Aβ42. Subsequent
cross breeding of APP and PS transgenic mice, as well as introduc-
tion of knockin PS1 mutations in APP mutated mice produced
doubly transgenic models. Different combinations of APP muta-
tions with PS1 or PS2 mutations have produced a variety of
APP/PS1 double transgenic models. One example is the PSAPP
model, produced by crossing PS1 M146L or M146V mutant mice
with Tg2576mice. These mice showedmarkedly accelerated amy-
loid deposition from an earlier age and increased overall plaque
numbers, as well as early cognitive deficits (Crews et al., 2010;
Elder et al., 2010; Philipson et al., 2010).
These models of AD have been used to explore various aspects
of its pathophysiology, ranging from Aβ metabolism and amy-
loid deposition to the effect of APOE genotype as well as tau
and NFT pathology (Götz et al., 2004). However, while the amy-
loid deposits in mouse models closely resemble human amyloid,
not all aspects of AD pathology are reproduced in transgenic
mice. Except for triple transgenic mice, which incorporate tau
mutation, the mice lack NFTs. Another difference is that amyloid
deposition is not associated with significant neuronal loss, apart
from when multiple mutations in either or both of APP and PS1
in double transgenic mice were introduced (Golde et al., 2006;
Fiala, 2007; Elder et al., 2010).
Despite these limitations mouse models play an important
role in ongoing research in AD, providing valuable insights into
pathophysiology. Furthermore, through the knowledge gained
these models are facilitating the search for new therapies and
improved methods for diagnosis.
MAGNETIC RESONANCE IMAGING IN MOUSE MODELS
Research into the imaging of AD pathology in transgenic AD
mouse models using MR has followed two general strategies. One
is the indirect measure of AD pathology reflected in changes
in relaxometry. The other is to develop techniques to utilize or
enhance the inherent contrast of amyloid plaques so as to directly
visualize them. Relaxometry studies involve statistical analysis
of measures of longitudinal and transverse relaxation values in
regions of interest for differences between AD transgenic mouse
brains and age-matched non-transgenic mouse brains that could
be attributed to Aβ deposition. The advantage of this method is,
being based on ROIs, it is less reliant on resolution (Muskulus
et al., 2009). In direct imaging of plaques the very small size of
many plaques requires a resolution with appropriately small voxel
dimensions. This increases scanning time and reduces the signal-
to-noise ratio, impeding the routine application of MR amyloid
imaging in in vivo research. Furthermore, the mechanisms under-
pinning signal changes are not yet fully understood (Braakman
et al., 2009; Chamberlain et al., 2011). Consequently there is a
great deal of ongoing research effort into methods for improv-
ing contrast and resolution in MR imaging and correlating this
imaging to the biophysics and physiology of AD pathology.
Helpern et al. (2004) were the first to acquire parametric maps
of T2 and T1 relaxation times and proton density to analyse
changes in measured values that may reflect altered cellular phys-
iology secondary to AD pathology (refer to Table 1). Of these
three measures they found only T2 was reduced in the hip-
pocampus, cingulate and retrosplenial cortex of APP/PS1 mice
compared to PS1 and non-Tg mice, while T1 and proton density
were unchanged between the genotypes. The correlation between
reduction in T2 relaxation time and increased amyloid burden
was later confirmed by other studies (Falangola et al., 2005a;
Vanhoutte et al., 2005; Borthakur et al., 2006; Braakman et al.,
2006; El Tannir El Tayara et al., 2006; El Tayara Nel et al., 2007).
Apart from confirming T2 changes in APP/PS1 mice, Falangola
et al. (2005b) applied an algorithm to register mapped T2 val-
ues to anatomical regions for comparison of differences between
groups of 18 months old APP/PS mice, PS mice and non-Tg
mice, as well as between groups of 6 weeks old and 18 months
old PS and non-Tg mice. Helpern et al. (2004) attributed the T2
reduction to the higher amyloid plaque burden in these areas.
However, this was inferred from the similarity of the pattern of
hypointensities demonstrated by ex vivoMR imaging in APP/PS1
mice to the distribution of plaques in histology described in the
literature.
El Tannir El Tayara et al. (2006) included histological analysis
of amyloid and iron along with measured T1, T2 and proton den-
sity values in a longitudinal study. They found that T2 changes
correlated with increasing amyloid load. However, T2 was also
correlated with age and the lack of a significant difference between
T2 in APP/PS1 mice and PS1 mice in most brain structures
suggests other age-related effects that are distinct from amyloid
deposition as main factors in T2 decrease. Furthermore, mean Fe
did not correlate with T2 or age, so that Fe may not participate
significantly in age-related T2 decrease. In another experiment T2
was measured in young APP/PS1 mice whose brains exhibited
amyloidosis in the subiculum but had no detectable iron accu-
mulation on histology (El Tayara Nel et al., 2007). The reduced
T2 in this region is seen by the authors to support the role
of other mechanisms in this effect, such as the hydrophobicity
of dense amyloid aggregates or other tissue alterations. A fur-
ther longitudinal analysis of quantitative parametric maps of T2
by Falangola et al. (2007), in which mice of various AD geno-
types (Tg2576, PS1, and PS/APP) were imaged suggested the
reduction in T2 involves both Aβ-dependent and Aβ-independent
mechanisms. In addition, it was suggested that iron could be a
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more significant factor for reducing T2 in older animals from 12
months.
Both Braakman et al. (2006) and more recently Teipel et al.
(2011) in their discussions support a role for plaque-associated
Fe in reducing T2 relaxation times. As with El Tannir El Tayara
et al. (2006) they registered T2 maps with histological investiga-
tions of amyloid and Fe, with Teipel et al. making additional use
of automated voxel-based analysis in studying T2 differences. The
consistent co-localization of Fe with plaques supports the asso-
ciation of Fe accumulation in plaques with reduced T2 (Teipel
et al., 2011). Vanhoutte et al. (2005) in their study mapped T∗2
relaxation with 3D gradient echo (GRE) imaging and found a
reduction in T∗2 values in the thalamus of singly transgenic mice,
where the majority of plaques were associated with Fe.
Taking a different approach Borthakur et al. (2006) analyzed
the transverse relaxation in the rotating frame, T1ρ and found
this was significantly reduced in the cortex and hippocampus of
APP/PS1 mice compared to non-Tg mice. Delineating plaques
on imaging and histology, they attributed the effect to amyloid
burden but noted it may also result from decreased blood flow
and blood volume. Another approach was taken by Thiessen et al.
(2010), who used DWI to map ADC values in the neocortex and
hippocampus of mice encoding two human APP mutations and
registering these with histology. They found no significant change
in ADC values compared to controls, suggesting Aβ deposition
does not contribute to any diffusional changes if and when they
are seen.
Zhang et al. (2004) were first to report on identification of
amyloid plaques on MRI imaging in AD transgenic mice with-
out exogenous contrast-enhancement (refer to Table 2). Using a
three-dimensional T2-weighted multiple spin echo (SE) protocol
to image ex vivo brains, they visualized numerous hypointensi-
ties, which corresponded to amyloid deposits seen on histology.
At the same time another group were also able to demonstrate
plaques on ex vivo images using a T2-weighted multi-slice fast SE
sequence (Helpern et al., 2004; Lee et al., 2004). Advancing on
these achievements, Jack et al. (2004) established the feasibility of
in vivo plaque imaging, acquiring scans of APP/PS1mice with T2-
weighted SE and T∗2-weighted GRE. In subsequent longitudinal
study they further validated the use of T2-weighted SE for imaging
amyloid plaques in vivo, visualizing plaques in mice at the earli-
est age of 9 months with a minimum size of 35μm (Jack et al.,
2005). In their comparison of T2-weighted SE to T∗2-weighted
GRE imaging, they found the disadvantage of longer acquisition
time with SE is offset by its superior ability to resolve smaller
plaques. Meanwhile the time efficiency of T∗2-weighted GRE is
countered by susceptibility artifacts and its overestimation of the
size of some plaques (Jack et al., 2004). Nonetheless there have
since been several more studies investigating amyloid imaging
with GRE sequences as well as further applications of SE protocols
(Vanhoutte et al., 2005; Borthakur et al., 2006; Braakman et al.,
2006; Faber et al., 2007; Chamberlain et al., 2009; Dhenain et al.,
2009; Meadowcroft et al., 2009; Wengenack et al., 2011).
One of the main aims of the MR studies is to reduce the scan-
ning time required. Zhang et al. (2004) required 14 h to acquire
their images while Lee et al. (2004)managed to scan ex vivomouse
brains in 2 h, a timemore compatible with in vivomouse imaging.
www.frontiersin.org October 2014 | Volume 8 | Article 327 | 9





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Frontiers in Neuroscience | Brain Imaging Methods October 2014 | Volume 8 | Article 327 | 10
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































www.frontiersin.org October 2014 | Volume 8 | Article 327 | 11
Adlard et al. Neuroimaging in Alzheimer’s disease
Jack et al. acquired in vivo T2-weighted SE and T∗2-weighted GRE
in 1 h 7min and 1 h 27min respectively. The time efficiency of
GRE sequences has meant in vivo scanning times of less than
an hour have been achieved (Faber et al., 2007; Dhenain et al.,
2009). Faber and co-workers, for example, were able to achieve
significant gains in time efficiency with the use of bright con-
trast obtained by correlated spectroscopy (COZY) revamped with
asymmetric z-GRE detection (CRAZED) sequences. However, in
these studies only thalamic plaques could be visualized and few if
any cortical plaques were seen (Faber et al., 2007; Dhenain et al.,
2009). On the other hand, Braakman et al. (2006) imaged corti-
cal plaques using a T2-weighted rapid acquisition with relaxation
enhancement (RARE) sequence that resulted in a scan time of
25min.
Thalamic plaques are more readily identified on MR imaging
(Dhenain et al., 2009). This has been attributed to variations in
tissue Fe deposition and Fe density in plaques (Jack et al., 2004;
Faber et al., 2007; Dhenain et al., 2009). This leads to the ques-
tion of the precise mechanisms by which transverse relaxation
is changed leading to contrast in plaques relative to surrounding
brain tissue on imaging. Comparing DAB-enhanced Perl’s stain-
ing for Fe with the distribution of amyloid deposits in histology
of mice brains shows they are frequently co-localized, indicating
Fe association with plaques (Jack et al., 2004; Lee et al., 2004;
Vanhoutte et al., 2005; Braakman et al., 2006). Thalamic plaques
have high concentrations of Fe associated with them (Faber et al.,
2007; Dhenain et al., 2009). Higher Fe concentrations produce
a “blooming effect” on T∗2-weighted imaging, which can lead to
overestimation of plaque size (Jack et al., 2004). However, plaques
in the cortex and hippocampus of AD mice have less associ-
ated Fe than thalamic plaques in mice and amyloid plaques in
human AD brains (Vanhoutte et al., 2005; Faber et al., 2007;
Leskovjan et al., 2009, 2011; Meadowcroft et al., 2009; Wengenack
et al., 2011). Illustrating this difference, in the studies using
T∗2-weighted GRE sequences only thalamic plaques were clearly
visualized (Vanhoutte et al., 2005; Faber et al., 2007; Dhenain
et al., 2009). The difference in size, morphology, mineral con-
tent and amyloid fibrillar structure in these thalamic plaques and
their lack of correlation with brain amyloidosis make them of lit-
tle use in the development of MR imaging (Dhenain et al., 2009;
Chamberlain et al., 2011; Wengenack et al., 2011). Nonetheless
the influence of Fe susceptibility effects on T2 relaxation is still
regarded as a major factor in achieving contrast when visualizing
plaques in the cortex and hippocampus of AD transgenic mice
(Helpern et al., 2004; Jack et al., 2004; Lee et al., 2004; Zhang
et al., 2004; Braakman et al., 2006; Chamberlain et al., 2009;
Meadowcroft et al., 2009; Wengenack et al., 2011).
Conversely, the fact that Fe is much reduced in amyloid
plaques in mice and secondly that not all visualized plaques con-
tain Fe suggest that there may be other sources of MR contrast in
amyloid plaques. Accelerated T2 relaxation in plaques may be par-
tially due to exchange between tissue water protons and protons
in plaque-associated proteins (Jack et al., 2004) or impaired cell
physiology with resultant reduced cerebral blood flow (Helpern
et al., 2004; Borthakur et al., 2006). It has also been suggested that
reduced T2 signal may be due to exclusion of water molecules
from the dense hydrophobic core of amyloid deposits (Lee et al.,
2004; Wengenack et al., 2011), though the fact that the proton
density in plaques is only slightly reduced compared to nor-
mal cortical tissue does not lend this support to this proposition
(Chamberlain et al., 2009; Wengenack et al., 2011). Part of the
difficulty in understanding the properties of plaques in MR imag-
ing has been due to the imprecise nature of co-registering the
plaques seen on imaging with histological localization of amyloid
deposits and Fe. Meadowcroft et al. overcame this difficulty by
using a coil optimized for scanning histological sections, allow-
ing very accurate co-registration between images and histology.
Thus, they were able to directly compare the difference in Fe con-
tent in plaques in APP/PS1 mice with human AD brain tissue
and control mice and analyse its effect on T2*-weighted imag-
ing. Iron was shown to play a role in the contrast in amyloid
in human AD brains on imaging, yet plaques in APP/PS1 mice
were as easily observed despite having significantly less Fe. This
plaque-associated signal loss may be explained by the interac-
tions of water with the highly compacted amyloid fibril mass
(Meadowcroft et al., 2009).
Attempts to enhance the endogenous contrast in plaques with
improved scanning efficiency and reliability has resulted in a wide
range of image acquisition techniques being investigated. These
have involved T2-weighted SE sequences and T∗2-weighted and
T1ρ GRE sequences, and included methods for contrast enhance-
ment such as susceptibility-weighted imaging (SWI) (refer to
Table 2). In a comparison of multiple techniques applied to
mouse brain imaging by Chamberlain et al. (2009), T∗2 was shown
to give superior plaque contrast-to-noise ratio (CNR) compared
to T2 while GRE gave consistently higher CNR compared to SE.
They further investigated the combination of SWI with multi-
ple asymmetric SE, GRE and multiple GRE to increase plaque
contrast. As with CRAZED, SWI relies on Fe for contrast enhance-
ment. They found that SW1 sequences provided the greatest
CNR on ex vivo imaging of cortical plaques. However, the use
of GRE and SWI in vivo is complicated by susceptibility artifacts
caused by the air-to-tissue and/or fat-to-skull interfaces. Jack and
co-workers consistently found T2-weighted SE sequences more
reliable in the detection of plaques as they are less reliant on their
Fe content (Jack et al., 2004; Chamberlain et al., 2009; Wengenack
et al., 2011).
One of the main concerns with direct imaging of amyloid
plaques is the lack of specificity in the signal changes that might
correspond to Aβ deposits (Poduslo et al., 2002; Jack et al., 2004).
T1 and proton density values do not differ significantly between
amyloid deposits and normal brain tissue (Helpern et al., 2004;
Chamberlain et al., 2009). On the other hand Fe, a major source
of accelerated T2 and T∗2 decay is non-specific. Consequently
blood vessels or microhaemorrhages can be evident in T2∗ and
SW1 images and thus also seen in normal brains (Poduslo et al.,
2002; Jack et al., 2004). A strategy aimed at overcoming these
initiatives, and analogous to radionuclide imaging, is the use of
amyloid-targeting ligands labeled with MR contrast-enhancing
molecules.
One molecule shown to bind with high affinity and specificity
to amyloid deposits was Aβ itself (Poduslo et al., 2002; Wadghiri
et al., 2003; Sigurdsson et al., 2008; Braakman et al., 2009; Yang
et al., 2011). Following Aβ labeled radionuclide experiments,
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Poduslo and co-workers surmized that labeling with gadolinium
(Gd) could enhance MR image contrast by acceleration of T1
relaxation and to a lesser extent T2 relaxation of nearby water
molecules. They were able to demonstrate contrast enhance-
ment of amyloid plaques on both T1-weighted and T2-weighted
images of ex vivo mouse brains following injection of synthetic
Aβ40 chelated to Gd prior to euthanization of the animal model.
Following this study Wadghiri et al. investigated the in vivo appli-
cation of enhancement with Aβ40 attached to Gd and monocrys-
talline iron oxide nanoparticles (MION). They were able to detect
plaques on in vivo T2-weighted SE and T∗2-weighted GRE images
but T1-weighted imaging required prohibitively long scan times.
Sigurdsson et al. showed again that Gd is able to enhance contrast
on T∗2-weighted imaging while Yang et al. investigated the use of
ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles
coupled to Aβ42 with T∗2-weighted GRE. T1-weighted imaging
is less sensitive to the magnetic susceptibility effects of Fe and
so demonstrated fewer artifacts from Fe-associated structures
such as white matter and blood vessels. Consequently there is
ongoing research into developing T1-weighted sequences for use
with Gd-labeled contrast enhancing agents (Wengenack et al.,
2008).
Two disadvantages are evident with the use of intravenously
administered Aβ peptides to label plaques. Firstly, the imper-
meable nature of the normal blood-brain-barrier necessitates
co-administration of mannitol or complexion of ligands with
polyamines such as putrescine to facilitate passage of the lig-
and into the brain to reach its target (Wadghiri et al., 2003;
Delatour et al., 2006; Braakman et al., 2009). Secondly, Aβ is
potentially toxic. Sigurdsson et al. (2008) developed a ligand using
the truncated Aβ1−30 peptide chelated to Gd. Other groups have
developed ligands based upon the amyloidophilic compound
Congo Red often used in histological staining (Higuchi et al.,
2005; Li et al., 2010). In a particularly novel approach, Higuchi
et al. (2005) utilized a Congo Red-based compound labeled with
19F. This compound was able to cross the blood-brain-barrier
and bind specifically to amyloid. 19F is MR-sensitive but present
in only very low concentrations in biological tissues, resulting in
very little non-specific background signal (Higuchi et al., 2005;
Braakman et al., 2009). Another strategy to overcome the toxic
effects of Aβ ligands is to use anti-Aβ monoclonal antibodies
linked to Gd (Wengenack et al., 2008).
In summarizing, the availability of Tg mouse models of AD
has greatly accelerated the progress made in MR amyloid imaging
by providing a convenient and efficient platform for develop-
ing techniques. In particular, the ability to correlate acquired
MR images with histology has been invaluable to understand-
ing pathophysiology and its MR behavior. Despite the limita-
tions so far, the advances that have been made show a greater
potential that remains achievable as technology and techniques
improve.
POSITRON EMISSION TOMOGRAPHY IMAGING
Following the development of functional FDG PET imaging in
patients with AD, the feasibility of detecting and monitoring
similar changes in cerebral metabolism in AD mouse models
was investigated (Reiman and Caselli, 1999; Valla et al., 2002,
2006, 2008; Dubois et al., 2010; Nicholson et al., 2010). FDG
autoradiography in the brains of a variety of AD mouse models,
ranging from single transgenic to triple transgenic mice, revealed
hypometabolism in the posterior cingulate cortex consistent with
findings in human studies (Reiman and Caselli, 1999; Valla et al.,
2002, 2006, 2008; Nicholson et al., 2010). However, these findings
did not translate to any detectable change on in vivo FDG PET in
mice (Kuntner et al., 2009).
Furthermore, amyloid imaging inmousemodels of AD has not
shown the same effective results as has been achieved in humans.
This contrasts with MRI studies, where conversely promising
findings in animal studies have yet to translate to consistent
human application. Initial PET studies using PIB in transgenic
ADmice did not detect any difference in ligand retention between
control mice and either Tg2576 or APP/PS1 (Klunk et al., 2005;
Toyama et al., 2005). The lack of significant difference has been
explained by reduced cerebral perfusion along with a reduction in
the density of high affinity ligand binding sites in the plaques in
transgenic mice (Klunk et al., 2005; Toyama et al., 2005; Kuntner
et al., 2009; Higuchi et al., 2010). The latter may be attributed to
the co-deposition of both rodent and human Aβ fibrils in mouse
plaques, disrupting the formation of high affinity binding sites
(Ye et al., 2006; Higuchi et al., 2010). Similarly, imaging with the
probe FDNNP in Tg2576 mice did not differentiate them from
control mice (Kuntner et al., 2009), despite its successful applica-
tion in a triple transgenic rat model of AD (Kepe et al., 2006; Teng
et al., 2011).
One way of overcoming the reduced density of high affinity
binding sites is by the administration of PIB synthesized with
high specific radioactivity, thereby reducing blockage of sites by
non-radioactive ligands and improving the plaque specific sig-
nal (Maeda et al., 2007; Higuchi, 2009). This method has enabled
demonstration of amyloidosis with PIB in the hippocampus and
neocortex of transgenic APP23 mice compared to age-matched
controls (Maeda et al., 2007, 2011; Higuchi, 2009). In turn, the
ability to image amyloid in vivo in transgenic mice enables longi-
tudinal studies for monitoring the effectiveness of anti-amyloid
interventions (Maeda et al., 2007, 2011; Higuchi, 2009). Also,
combining amyloid imaging with other PET ligands, such as those
specific for markers of neuroinflammation, can help further the
understanding of the associated molecular and cellular mecha-
nisms of AD pathology and experimental therapeutic approaches
(Maeda et al., 2007, 2011; Higuchi, 2009; Higuchi et al., 2010).
Studies exemplifying this have demonstrated a decline in hip-
pocampal amyloid following passive immunization with anti-Aβ
antibodies in transgenic mice, while concurrently revealing asso-
ciated microglial activation and increased neuroinflammation
(Maeda et al., 2007, 2011; Higuchi, 2009).
Notwithstanding these important advances, the use of PET
in preclinical small animal imaging in AD remains constrained
by technical considerations. The spatial resolution, of current
generation scanners, which can range from 0.5 to 3mm, is insuf-
ficient in the context of the small size of mouse brain structures
(Nikolaus et al., 2004; Kuntner et al., 2009; Dubois et al., 2010).
Difficulties also arise from partial volume error that affects vol-
ume definition and radioactivity measurements in small volumes
of interest (Nikolaus et al., 2004; Kuntner et al., 2009).
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COMPUTED TOMOGRAPHY IMAGING AND MAGNETIC RESONANCE
SPECTROSCOPY
The superior resolution of MR for visualizing brain tissue has
meant CT has been seldom utilized as an option for imaging amy-
loid pathology in mice. Nonetheless, a few studies have explored
CT neuroimaging. Hyde et al. (2009) combined structural infor-
mation from CT with fluorescence molecular tomography with
a fluorescent oxazine dye for in vivo quantification of amyloid
plaque burden in APP23 mice. Others have applied CT directly
to imaging amyloid plaques, either with phase-contrast X-ray CT
(Noda-Saita et al., 2006) or with diffraction-enhanced imaging
(DEI) in micro-CT mode (Connor et al., 2009). Both Noda-Saita
et al. (2006) and Connor et al. (2009) demonstrated individual
plaques on ex vivo imaging with high spatial resolution compara-
ble to histological analysis. However, the high level of irradiation
associated with phase-contrast CT and its inability to image the
brain within the skull meant it could not be applied in vivo
(Noda-Saita et al., 2006). According to Connor et al. DEI could
overcome the issue of in vivo imaging by using higher energy
x-rays to reduce attenuation from the skull. Nonetheless, these
limitations of plaque imaging with CT and the lack of any clear
advantage over MR plaque imaging has resulted in no studies
being published to date with in vivo CT imaging in AD mouse
models.
In contrast, MRS has had greater utility in evaluating patho-
logical changes in a number of AD mouse models (Marjanska
et al., 2005; von Kienlin et al., 2005; Oberg et al., 2008; Chen et al.,
2009; Salek et al., 2010; Xu et al., 2010). Analysis of the metabolic
profile of PS2APP (von Kienlin et al., 2005) and APP/PS1 mice
(Marjanska et al., 2005; Oberg et al., 2008) by in vivo MRS
revealed significant decreases in the NAA and glutamate levels
relative to Cr with advancing age. These changes in transgenic
models, in particular the APP/PS1 model are concordant with
those seen in human AD brains (Marjanska et al., 2005; Michaelis
et al., 2009). Marjanska and co-workers also observed an increase
with age in the concentration of myo-inositol (m-Ins), a marker
of glial activation, in APP/PS1 mice compared to wild-type con-
trols. This finding was later confirmed by Chen et al. (2009)
and has confirmed the significance of m-Ins as an alternative
metabolic marker to NAA, enabling investigation of other disease
processes in AD (Oberg et al., 2008). Taken together the results
from these studies provide good support for the role of MRS in
preclinical research in AD.
CURRENT STATUS OF NEUROIMAGING BIOMARKERS IN
ALZHEIMER’S DISEASE
Technological advances in neuroimaging have yielded a burgeon-
ing wealth of information on the pathology of AD. Coupled
with our growing understanding of the molecular and cellular
basis of the disease, these advances have opened new possibili-
ties and potential for new approaches. Foremost of these advances
has been that of PET, which has exemplified the versatility of
neuroimaging in both preclinical and clinical research in AD.
Early development of ligands specific for neuroreceptors revealing
changes in neurotransmitter systems, such as the cholinergic sys-
tem and dopaminergic system, together with functional imaging
enabled by FDG-PET, provided initial insights into the molecular
mechanisms of AD (Vallabhajosula, 2011). However, the devel-
opment of amyloid-binding probes has markedly enhanced the
potential for PET imaging in the diagnosis of AD. The initial
ligand synthesized for this purpose, FDNNP, which exhibits non-
specific binding to both amyloid and NFT pathology, was quickly
surpassed by the amyloid-specific ligand [11C]-PIB. Since the
introduction of PIB, in vivo amyloid imaging has demonstrated
the capacity to diagnose AD with good accuracy and to differen-
tiate AD from dementia due to a number of other causes. It has
also provided immense insights into clinicopathology, revealing
key information that has greatly influenced our current under-
standing of the amyloid hypothesis of AD pathogenesis. The lack
of correlation between amyloid burden and clinical severity in
AD, along with the significant proportion of cognitively normal
elderly with detectable amyloid, has recently resulted in the pres-
ence of cerebral amyloid being viewed in an increasingly complex
manner in disease development. That Aβ pathology plays a key
role remains widely accepted, but the pathological mechanisms
of AD may occur prior to the formation of amyloid plaques.
Nonetheless, the utility of amyloid imaging is firmly established
and is reflected by ongoing development into amyloid-targeting
ligands (Vallabhajosula, 2011), particularly 18F-labeled ligands
that exhibit more specific binding and have greater clinical avail-
ability due to the 2 h half-life.
The evolution of MRI techniques has also provided impor-
tant new perspectives for the development of MRI biomarkers
in AD. There are now a number of quantitative structural MRI
studies demonstrating volume loss in the medial temporal lobe,
particularly the hippocampus, as a significant and early marker
of disease development in AD (Ewers et al., 2012) [a recent
study using MR imaging in infants (2–25 months of age) of dif-
ferent apolipoprotein E status revealed that APOE E4 carriers
had decreased gray matter volume in areas typically affected in
AD, raising the possibility that a genetic predisposition to AD
is reflected by early anatomical alterations in the brain (Dean
et al., 2014)]. The neuronal loss underpinning the macroscopic
regional gray matter atrophy seen on T1-weighted MRI can be
further investigated at the microscopic level, by techniques such
as MTR and MRS. In a recent study of quantitative parametric
mapping of MTR parameters and gray matter volumetric maps
in AD patients, Giulietti et al. (2012) suggest that the reduc-
tion in MTR may reflect not only amyloid deposition, but also
metabolic derangement due to mitochondrial dysfunction, as
the affected regions exhibit both PIB accumulation and reduced
glucose metabolism on FDG-PET. Hence MTR can give infor-
mation complementary to conventional structural MRI, which
may have further value in investigating other groups such as
MCI subjects and other dementia patients. Similarly MRS, by
enabling detection of metabolites reflecting neuronal loss and
gliosis can provide further information on pathophysiological
changes to complement structural imaging changes in MCI and
early AD. Using this multimodal approach, Westman et al. (2011)
in their multivariate analysis of MRI volumetric measures and
MRS measures improved the discrimination between early AD
patients and healthy controls. DTI has also been used to reveal
damage to white matter tracts in and between known affected
areas in AD, such as in the posterior cingulum and between the
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prefrontal cortex and the medial temporal lobe or parietal cortex.
Advanced MRI techniques have been applied to reveal impor-
tant information on the consequences of neuronal dysfunction
and neuronal loss. Axonal degeneration and white matter changes
that occur secondary to neuronal loss can be investigated with
DTI. Yukashev and colleagues demonstrated that both macro-
scopic changes shown by volumetric analysis and microstructural
changes revealed by DTI lead to metabolic changes in the pos-
terior cingulate cortex (Yakushev et al., 2011a,b). Hattori et al.
(2012) utilized DTI to analyse the fornix, which contains efferent
fibers from the hippocampus, in AD patients and patients with
normal pressure hydrocephalus (NPH) which is another cause of
progressive dementia. Their tract-specific analysis revealed differ-
ing patterns of damage between NHP and AD patients, suggesting
the potential of this approach in differentiating these two causes
of dementia. Functional MRI, measuring changes in regional
brain activity arising from gray and whitematter changes and par-
ticularly loss of functional connectivity, is another emerging MRI
technique able to complement structural MRI. In their analysis
of volumetric gray matter change and resting state fMRI mea-
surements, Dai et al. (2012) were able to discriminate between
early AD patients and healthy controls with an accuracy of 89.5%.
However, validation of these MRI techniques, applied individu-
ally and in multimodal approaches requires further investigation
in larger groups (Drago et al., 2011).
Recent research publications have shown a clear evolu-
tion from single-modality imaging to multimodality imaging
studies of neuroimaging biomarkers of AD. The complemen-
tary information yielded by multiple imaging approaches gives
greater insight into the pathophysiological processes occurring
in vivo. An improved understanding of the temporal relation-
ship of emerging neuroimaging biomarkers is also important.
The dynamic model of imaging biomarkers in AD (Frisoni et al.,
2010; Jack et al., 2010; Cavedo and Frisoni, 2011; Ewers et al.,
2012) reflects the developing concept of AD as a continuum of
pathophysiological processes, with clinical AD being a late mani-
festation (refer to Figure 1). Amyloid imaging not only supports
the classification of amnestic MCI as the prodromal stage, but
also provides evidence for an asymptomatic preclinical stage in
which the pathological processes for AD have already been trig-
gered (Cavedo and Frisoni, 2011; Ewers et al., 2012). PIB imaging
has revealed up to 50% of MCI patients and up to 30% of
cognitively normal elderly have significant amyloid deposition,
associated with changes in brain structure and function (Ewers
et al., 2012; Mormino et al., 2012). In MCI, both PIB positiv-
ity and the presence and rate of hippocampal atrophy on MRI
are predictive of conversion to clinical AD. However, as reflected
in the dynamic imaging biomarker model, the amyloid bur-
den has reached a plateau in MCI and hippocampal atrophic
changes are already significant following the onset of clinical AD
(Cavedo and Frisoni, 2011; Ewers et al., 2012). This suggests that
biomarkers have less relevance in the latter stages of the disease
continuum. Furthermore, PET imaging and structural MRI do
not offer any advantage in accuracy and utility over clinical cri-
teria for AD diagnosis, hence part of the reason why they are
yet to be accepted as part of diagnostic criteria (McKhann et al.,
2011).
FIGURE 1 | Hypothetical model of various neuroimaging biomarkers
and their predicted utility during disease progression. Adapted from
Ewers et al. (2011) and Frisoni et al. (2010).
Consequently, the focus of neuroimaging has now shifted to
defining the preclinical stage of AD (Sperling et al., 2011). As
mentioned, a proportion of cognitively normal individuals are
known to harbor significant amyloid as evidenced by PIB reten-
tion, with the onset of this deposition occurring after the age of
50 in people without familial AD (Ewers et al., 2012). It is pos-
sible that slight elevations in PIB in cognitively normal elderly
may have biological relevance (Mormino et al., 2012).When stud-
ied with FDG-PET, cognitively normal individuals carrying the
ApoE ε4 demonstrate early abnormalities (Ewers et al., 2012).
Similarly, PIB-positive elderly may demonstrate lack of deacti-
vation and disrupted functional connectivity in the DMN with
fMRI, and greater atrophy in the hippocampus and cingulate
cortex on structural MRI (Ewers et al., 2012). Consequently,
defining preclinical AD has been a major focus, leading to rec-
ommendation of a research framework for working toward this
goal by the National Institute on Aging—Alzheimer’s Association
workgroups (Sperling et al., 2011). Neuroimaging is an inte-
gral component in developing the preclinical AD definition, as
reflected in the recommended draft operational research frame-
work. Further research, particularly longitudinal studies, are
needed to contribute toward elucidating the full continuumof AD
pathophysiology.
Our understanding of the pathological mechanisms in AD has
been advanced by the extensive application of neuroimaging tech-
niques to visualize and understand in vivo neuropathology. The
role of synaptic failure in AD has informed studies in fMRI, while
neuroinflammation and mitochondrial dysfunction is important
in interpretation of MRS and MTR findings. Additionally, the
role of metal dyshomeostasis in AD pathogenesis has suggested
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other approaches to imaging. Variations in Fe distribution in the
brain are detectable by MRI (Haacke et al., 2005; Bartzokis et al.,
2007), thereby suggesting it can be potentially be applied to study
the analysis of Fe dysregulation in AD. Techniques to analyse the
distribution of Fe through variations in magnetic relaxivity (R
and R∗) values have been carried out in post-mortem AD brains
(Antharam et al., 2012). Nakada et al. (2008) utilized SWI in MRI
on a 7T scanner to visualize plaque-like pathology in patients
with AD. However, their sample size was small and their study
could not be correlated with histology. Studies of other aspects
of AD pathology, such as the strengthening evidence for the pri-
mary role of Aβ oligomers in neurotoxicity and the importance
of NFTs in the pathology cascade, will require novel neuroimag-
ing developments. Further insights into the molecular aspects
of AD may provide opportunities for clinical imaging applica-
tions, and enable further progress on defining preclinical AD.
Ultimately, neuroimaging based upon AD patholophysiologymay
bring about the realization of accurate early diagnosis, thereby
providing the opportunity for early preventative interventions,
which can bemonitored for efficacy by tracking changes in disease
processes using neuroimaging techniques.
TRANSLATING NEUROIMAGING: UNDERSTANDING AND
INTEGRATING PATHOPHYSIOLOGICAL MECHANISMS IN
MOUSE MODELS
Transgenic ADmousemodels are imperfect replicas of the human
disease. This has significant implications for the application and
interpretation of current neuroimaging findings in animal mod-
els. The expression of human Aβ in mice affects the physicochem-
ical properties of the formed plaques, which contain both human
and rodent Aβ. Apart from altered fibril structure, mouse plaques
differ in the concentration of the associated metals, in particu-
lar their Fe content. Furthermore, these models fail to reproduce
the full spectrum of AD pathology evident in human brains, sug-
gesting that other factors or key pathological mechanisms are
missing. For example, single transgenic mice do not exhibit neu-
ronal loss despite Aβ deposition, though this is changed with the
introduction of multiple genes (Elder et al., 2010). Also, NFTs are
not found in transgenic AD mice unless a tau mutation is intro-
duced (Elder et al., 2010; Balducci and Forloni, 2011), However,
these triple-transgenic mice may not be wholly relevant to AD
as tau mutations are not a feature of AD. It may be that the
much shorter lifespan of mice precludes key necessary patholog-
ical processes associated with human aging, or alternatively these
variations may again be attributed to differences between mouse
and human proteins (Elder et al., 2010). Another suggestion is,
due to their limited AD phenotype, transgenic mice may instead
represent models of preclinical AD (Woodhouse et al., 2009; Zahs
and Ashe, 2010). In either case, the transgenic mouse model is
non-etheless an invaluable asset in the investigation of the patho-
physiological mechanisms of the disease. Mouse studies have
helped elucidate the role of Aβ accumulation and other patholog-
ical processes, including oxidative stress, inflammation and metal
dyshomeostasis in the development of neuropathology (reviewed
in Balducci and Forloni, 2011). Bidirectional translation between
human research and preclinical studies in mice is also funda-
mental in developing our understanding of AD and furthering
advances in neuroimaging biomarkers (Higuchi et al., 2010).
Furthermore, the time efficiency and cost-effectiveness afforded
by the accelerated formation of neuropathology and their short
lifespan, makes them particularly useful for longitudinal neu-
roimaging studies (Strome and Doudet, 2007; Waerzeggers et al.,
2010).
The most extensive use of mouse models for neuroimaging
in AD has been in MR imaging studies. The technical diffi-
culties of applying cognitive paradigms to provoke responses
in rodents and the need to anaesthetize them for scanning
has meant that only a few fMRI studies have been reported
(Benveniste et al., 2007), The detection of brain atrophy in
transgenic mice has varied between structural MRI studies, and
atrophic changes do not appear to correlate with the degree of Aβ
deposition (Balducci and Forloni, 2011). Furthermore, the pat-
tern and mechanisms of atrophy in mice appear to differ from
those in human AD (Delatour et al., 2006; Maheswaran et al.,
2009). These inconsistencies in structural imaging studies may
be addressed using newer mouse models, such as the APPxPS1-
Ki mouse, which exhibits both early onset amyloid-β deposition
and subsequent neuronal loss (Faure et al., 2011). Other stud-
ies, using MRS in transgenic mice to investigate changes in
the metabolites NAA, choline and mIns, have closely paralleled
findings from human studies (Barba et al., 2008), and have pro-
vided important insights into the progression of pathological
changes. MRS changes are associated with areas exhibiting amy-
loid deposition (Salek et al., 2010; Xu et al., 2010), though altered
metabolites may be detectable in mice before accumulation of
plaques and major histological changes, at an early stage of the
disease.
By far the majority of endeavors using MRI in transgenic
mice have been for developing imaging of amyloid plaques (see
Figure 2B). Various image acquisition protocols have now been
investigated to improve the resolution and the plaque-specific
contrast and to reduce scanning times. Techniques sensitive to the
susceptibility effects of plaques, T2- and T∗2-weighted imaging are
able to provide good contrast for plaque imaging, while further
enhancement with SWI has the potential to shorten the dura-
tion of scanning to clinically acceptable times before MR amyloid
imaging is translated from preclinical mouse studies to human
clinical research. Despite promising results from numerous stud-
ies, a number of issues are still to be resolved. The majority
of mouse imaging studies utilize ultra-high field strength mag-
nets of 9.4 Tesla, while most clinical scanner magnets are 1.5
or 3 Tesla. Excluding susceptibility artifacts, arising from other
structures giving similar signal on T2- and T∗2-weighted images
or from the skull-air interface on SWI, is a significant technical
challenge. Also, the relationship between the MRI signal and the
intrinsic biochemical properties of amyloid plaques needs further
clarification. Mouse plaques contain less Fe than human plaques
(Leskovjan et al., 2009; Meadowcroft et al., 2009), which suggests
different mechanisms are responsible for the decay of trans-
verse relaxation in mouse plaques compared to human plaques
(Meadowcroft et al., 2009). Alternatively, enhancing contrast with
plaque-specific contrast agents could circumvent the reliance
on the intrinsic susceptibility signal of plaques using MRI. As
with PET ligand development, mouse models lend themselves
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FIGURE 2 | (A) [11C]-PIB-PET images illustrating amyloid depositions in
brains of an AD patient (axial view) and different strains of APP transgenic or
PS-1/APP double transgenic mice (coronal view) merged onto anatomical
MRI maps. Human and mouse images are differently scaled according to the
maximal binding potential for the radiotracer in each species, as indicated by
vertical bars from Higuchi et al. (2010). (B) Five-way anatomic spatial
coregistration of a 24-month-old APP/PS1 AD transgenic mouse brain. Ex
vivo MRI scans of matched sections imaged using either a (A) T2SE or (D) T∗2
GE pulse sequence. Matched adjacent histological sections processed with
(G) DAB-enhanced iron staining, (J) thioflavine S amyloid staining, or
(M) anti-Aβ peptide immunohistochemistry. Scale bar = 500μm. (B,E,H,K,N)
Higher magnification of hippocampal plaques positively matched by spatial
coregistration. Corresponding plaques are labeled with numbers when
present in a particular section. (C,F,I,L,O) Higher magnification of thalamic
plaques positively matched by spatial coregistration. (O) Scale bar = 100μm
from Wengenack et al. (2011).
readily to the development and testing of plaque specific contrast
agents.
In contrast to MRI imaging, the PET amyloid imaging has
been less effectively translated to transgenic mouse models (see
Figure 2A). As previously mentioned, a major reason for this is
the paucity in high affinity ligand binding sites in mouse amyloid,
which can partly be overcome by synthesizing ligands with higher
specific radioactivity (Waerzeggers et al., 2010). Improving the
spatial resolution of preclinical PET scanners is another challenge.
Most studies of new PET ligands targeting amyloid have relied on
ex vivo autoradiography to localize ligand binding in the brains of
transgenic mice (Ono et al., 2011; Vallabhajosula, 2011). Yousefi
et al. (2011), in their evaluation of [11C]-Labeled Imidazo[2,1-
b]benzothiazoles as PET tracers, demonstrate that improvements
in small animal PET scanners have enabled in vivo imaging
in mouse models to contribute toward ligand development.
Furthermore, in vivo PET in mice provides immense potential
for furthering the understanding of pathological mechanisms and
development of ligands specific for AD neuroimaging (Higuchi
et al., 2010; Klohs and Rudin, 2011). Multi-tracer studies have
been particularly valuable in elucidating pathological relation-
ships in mice, such as the loss of noradrenergic neurons and
inflammatory reactions with decreased metabolism (Waerzeggers
et al., 2010). Maeda et al. (2007) demonstrated not only the fea-
sibility of PET amyloid imaging of transgenic mice using PIB
with high specific radioactivity, but also combined PIB with PET
markers for glial activation application in longitudinal monitor-
ing of immunotherapy in mice. Their subsequent study investi-
gating glial responses in mouse models of AD and tau pathologies
with PET offered important insights into the pathological mech-
anisms at work (Maeda et al., 2011). In particular, their findings
suggest a link between upregulation of microglial inflammatory
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responses by Aβ deposits and conversion of glial responses to
a neurotoxic form mediating tau pathology and neuronal loss
(Higuchi et al., 2010; Maeda et al., 2011). This may explain the
absence of neuronal loss seen in AD mouse models that lack
tau pathology (Higuchi et al., 2010). The stimulation of specific
immune responses by Aβ and its adverse effect on tau pathol-
ogy and neuronal survival has implications for immunotherapy
in the treatment of AD (Higuchi et al., 2010; Maeda et al., 2011).
These findings highlight the value of PET imaging in the evaluat-
ing therapeutic interventions, by enabling key pathophysiological
mechanisms to be monitored.
As neuroimaging in AD mouse models advances in parallel
to clinical research, new imaging approaches will be informed
by developments in our understanding of AD pathophysiol-
ogy. Structural MRI has gained new perspectives from incor-
porating DTI and MTI, by elucidating early microstructural
changes that can be correlated with the development of atrophic
changes. Analysis methods such as voxel-basedmorphometry and
deformation-based morphometry are being used to study sub-
tle atrophy in vulnerable brain regions in AD transgenic mice.
MR amyloid imaging can be expected to further advance, with
ongoing developments in amyloid specific MR contrast agents.
For example, a novel recent approach taken by Higuchi et al.
(2005) and further developed by Yanagisawa et al. (2011) involved
labeling amyloid with 19F-containing compounds. As biological
tissues contain no 19F, detection of plaques can be improved by
reduction in the background non-specific signal (Higuchi et al.,
2005; Yanagisawa et al., 2011). Similarly novel approaches for
PET ligand development have been explored. An example of
this is the targeting of metal-associated Aβ aggregates with the
metal chelator, clioquinol labeled with an iodine radioisotope
(Roney et al., 2009; Kulkarni et al., 2010). In a parallel approach,
Fodero-Tavoletti et al. (2010) used bis(thosemicarbazonato) CuII
complexes, which have been shown to facilitate intracellular Cu
delivery, coupled with positron emitting 64Cu as a PET tracer. As
this approach does not rely on uptake of Cu by plaques and con-
sequently does not correlate with amyloid burden, they suggest it
may offer complementary information to other methods.
CONCLUSION
Our understanding of the pathophysiological mechanisms of AD
has been significantly enhanced through the application of neu-
roimaging to visualize these processes in vivo. At the same time,
our knowledge of AD pathophysiology is helping to inform new
directions for imaging approaches for studying neuropathology.
With the focus shifted to earlier diagnosis at a prodromal or
even asymptomatic stage of AD, current imaging methods are
important to define these stages. Early diagnostic criteria will
depend not only on current biomarkers combined in a multi-
modal approach, but also the development of novel techniques
for neuroimaging that may offer more specific biomarkers of dis-
ease, intimately reflecting the underlying pathophysiology. This is
also important to the efficacy and success of developing new inter-
ventions for altering the course of the disease. Ultimately, without
effective interventions, the ability to diagnose AD at any stage will
allow us to be little more than informed observers to an unfolding
health crisis.
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